Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study

Arti Hurria(Memorial Sloan Kettering Cancer Center), Kayo Togawa(Memorial Sloan Kettering Cancer Center), Supriya G. Mohile(Memorial Sloan Kettering Cancer Center), Cynthia Owusu(Memorial Sloan Kettering Cancer Center), Heidi D. Klepin(Memorial Sloan Kettering Cancer Center), Cary P. Gross(Memorial Sloan Kettering Cancer Center), Stuart M. Lichtman(Memorial Sloan Kettering Cancer Center), Ajeet Gajra(Memorial Sloan Kettering Cancer Center), Ravi Bhatia(Memorial Sloan Kettering Cancer Center), Vani Katheria(Memorial Sloan Kettering Cancer Center), S. Klapper(Memorial Sloan Kettering Cancer Center), Kurt Hansen(Memorial Sloan Kettering Cancer Center), Rupal Ramani(Memorial Sloan Kettering Cancer Center), Mark S. Lachs(Memorial Sloan Kettering Cancer Center), F. Lennie Wong(Memorial Sloan Kettering Cancer Center), William P. Tew(Memorial Sloan Kettering Cancer Center)
Journal of Clinical Oncology
August 2, 2011
Cited by 1,818Open Access
Full Text

Abstract

PURPOSE: Older adults are vulnerable to chemotherapy toxicity; however, there are limited data to identify those at risk. The goals of this study are to identify risk factors for chemotherapy toxicity in older adults and develop a risk stratification schema for chemotherapy toxicity. PATIENTS AND METHODS: Patients age ≥ 65 years with cancer from seven institutions completed a prechemotherapy assessment that captured sociodemographics, tumor/treatment variables, laboratory test results, and geriatric assessment variables (function, comorbidity, cognition, psychological state, social activity/support, and nutritional status). Patients were followed through the chemotherapy course to capture grade 3 (severe), grade 4 (life-threatening or disabling), and grade 5 (death) as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: In total, 500 patients with a mean age of 73 years (range, 65 to 91 years) with stage I to IV lung (29%), GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or other (6%) cancer joined this prospective study. Grade 3 to 5 toxicity occurred in 53% of the patients (39% grade 3, 12% grade 4, 2% grade 5). A predictive model for grade 3 to 5 toxicity was developed that consisted of geriatric assessment variables, laboratory test values, and patient, tumor, and treatment characteristics. A scoring system in which the median risk score was 7 (range, 0 to 19) and risk stratification schema (risk score: percent incidence of grade 3 to 5 toxicity) identified older adults at low (0 to 5 points; 30%), intermediate (6 to 9 points; 52%), or high risk (10 to 19 points; 83%) of chemotherapy toxicity (P < .001). CONCLUSION: A risk stratification schema can establish the risk of chemotherapy toxicity in older adults. Geriatric assessment variables independently predicted the risk of toxicity.


Related Papers